Concurrence of Ocular Cicatricial Pemphigoid in Chronic Ocular Graft-Versus-Host Disease.
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
21 Dec 2023
21 Dec 2023
Historique:
received:
17
05
2023
accepted:
04
08
2023
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
21
12
2023
Statut:
aheadofprint
Résumé
The aim of this study was to report a series of 3 patients with ocular graft-versus-host disease (oGVHD) with progressive cicatricial conjunctival changes who were diagnosed with ocular cicatricial pemphigoid (OCP) after conjunctival biopsy. This study was a retrospective case series. Three patients who received hematopoietic stem cell transplantation for hematologic malignancies developed oGVHD and subsequently were diagnosed with OCP. Case 1 was a 73-year-old woman with oGVHD who developed symblepharon and showed positive IgA, IgG, and C3 staining of the basement membrane zone (BMZ) on conjunctival biopsy, consistent with OCP. She was systemically treated with tacrolimus and prednisone with resolution of conjunctival inflammation. Case 2 was a 68-year-old man with oGVHD who developed symblepharon, severe dry eye, and corneal epithelial defect. An initial conjunctival biopsy was negative, but a repeat biopsy performed 10 years later showed positive BMZ IgA and IgG staining. Healing of the epithelial defect was achieved after treatment with high-dose systemic cyclosporine. Case 3 was a 75-year-old woman with oGVHD who had a nonhealing corneal epithelial defect and symblepharon with positive IgA BMZ staining on conjunctival biopsy, consistent with OCP. The patient responded well to methotrexate with healing of the epithelial defect. Although low-grade conjunctival fibrotic changes may be observed in chronic oGVHD, development of severe and progressive cicatricial changes, including symblepharon formation, should prompt consideration of biopsy to rule out concurrent OCP, the management of which differs from that of oGVHD.
Identifiants
pubmed: 38128104
doi: 10.1097/ICO.0000000000003386
pii: 00003226-990000000-00440
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. Arch Ophthalmol. 1989;107:1343.
Livesey SJ, Holmes JA, Whittaker JA. Ocular complications of bone marrow transplantation. Eye. 1989;3:271–276.
Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983;90:4–13.
Nassar A, Tabbara KF, Aljurf M. Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol. 2013;27:215–222.
Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58:233–251.
Wang K, Seitzman G, Gonzales JA. Ocular cicatricial pemphigoid. Curr Opin Ophthalmol. 2018;29:543–551.
Stan C, Diaconu E, Hopirca L, et al. Ocular cicatricial pemphigoid. Rom J Ophthalmol. 2020;64:226–230.
Karwacka E, Ołdakowska-Jedynak U, Brydak-Godowska J, et al. Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc. 2006;38:292–294.
Nonnenmacher A, Borgmann H, Mahmoud H, et al. Augenveränderungen nach Knochenmark-Transplantation. Klin Monbl Augenheilkd. 1985;186:34–35.
Shulman HM, Cardona DM, Greenson JK, et al. NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 pathology working group report. Biol Blood Marrow Transplant. 2015;21:589–603.
Labowsky MT, Stinnett SS, Liss J, et al. Clinical implications of direct immunofluorescence findings in patients with ocular mucous membrane pemphigoid. Am J Ophthalmol. 2017;183:48–55.
Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663.
Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–379.
Ahmed M, Zein G, Khawaja F, et al. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res. 2004;23:579–592.
Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111:45–52.
Shimanovich I, Nitz JM, Zillikens D. Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid. J Am Acad Dermatol. 2017;77:700–705.e3.
Ong HS, Setterfield JF, Minassian DC, et al. Mucous membrane pemphigoid with ocular involvement. Ophthalmology. 2018;125:496–504.
Wang M, Lehman JS, Camilleri MJ, et al. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: a single-center retrospective review. J Am Acad Dermatol. 2019;81:472–479.